Core Viewpoint - Ascentage Pharma-B (06855) announced key appointments to its board, including the establishment of a new R&D committee, effective December 26, 2025 [1] Group 1: Board Appointments - Dr. Debra Yu will be appointed as a new member of the Board Nomination Committee, effective December 26, 2025 [1] - Dr. David Sidransky will be appointed as the Chief Independent Non-Executive Director, effective December 26, 2025, to act as an intermediary between other directors and the company's shareholders, and to communicate with other directors and shareholders when normal communication channels with the board chair or management are insufficient [1] Group 2: R&D Committee Establishment - The R&D Committee will be established, effective December 26, 2025, consisting of scientists, physicians, and business experts responsible for overseeing R&D strategies, product lines, investments, and emerging trends while managing risks and ensuring alignment with business objectives [1] - Dr. Marc E. Lippman will serve as the chair of the R&D Committee, with Dr. David Sidransky and Dr. Wang Shaomeng as members [1]

亞盛醫藥集團 ASCENTAGE PHARMA GROUP INTERNATIONAL 葉長青先生 任為先生 David Sidransky博士 （首席獨立非執行董事） Marina S. Bozilenko女士 Debra Yu博士 Marc E. Lippman, MD （於開曼群島註冊成立的有限公司） （股份代號：6855） 董事名單與其角色和職能 亞盛醫藥集團董事會（「董事會」）成員載列如下： 執行董事 楊大俊博士 （主席） 非執行董事 王少萌博士 呂大忠博士 獨立非執行董事 董事會設有三個委員會。各董事會委員會的組成載列如下： | | 董事委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | 研發委員會 | | --- | --- | --- | --- | --- | --- | | 董事 | | | | | | | 楊大俊博士 | | | | | | | 王少萌博士 | | | | | M | | 呂大忠博士 | | M | | | | | 葉長青先生 | | C | M | | | 1 | 董事委員會 | 審計委員會 | 薪酬委員會 | 提名委員會 | 研發委員會 | | --- | - ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） （股份代號：6855） 董事會欣然宣佈，David Sidransky博士將獲委任為首席獨立非執行董事（「首席獨 立非執行董事」），自2025年12月26日起生效，以(i)作為其他董事與本公司股東 之間的中間人；及(ii)在與董事會主席或本公司管理層的正常溝通渠道不足的情況 下，可與其他董事及本公司股東聯絡。首席獨立非執行董事並非本公司的行政職 位，且不擔任本集團的任何管理角色，亦不會承擔單獨或相較於其他獨立非執行 董事更高級別的責任或義務。 1 成立研發委員會 (1)提名委員會組成之變動； (2)委任首席獨立非執行董事； (3)成立研發委員會；及 (4)有關根據2022年受限制股份單位計劃進一步授出獎勵及 根據首次公開發售後購股權計劃授出購股權的補充公告 提名委員會組成之變動 亞 ...

Core Viewpoint - The Hong Kong pharmaceutical market is experiencing a downturn, with the Hong Kong Stock Connect Innovation Drug ETF (159570) declining by 1.14% and over 25% from its previous high, despite a significant trading volume of over 1.44 billion yuan [1][4]. Group 1: Market Performance - The Hong Kong Stock Connect Innovation Drug ETF (159570) has seen a three-day decline, reaching a new low, with a total trading volume exceeding 14.4 billion yuan [1]. - As of December 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) is over 21.9 billion yuan, leading among its peers [1]. - Major stocks within the ETF, such as King’s Bio and Kelun-Bio, have experienced declines, with King’s Bio dropping over 3% [4][5]. Group 2: IPO Activity - On December 30, Insilico Medicine, a generative AI-driven biopharmaceutical company, successfully listed on the Hong Kong Stock Exchange, marking it as the first AI biopharmaceutical company to do so under the main board listing rules [3]. - The IPO raised a total of 2.277 billion Hong Kong dollars, making it the highest fundraising biopharmaceutical IPO in Hong Kong for the year [3]. Group 3: Industry Trends - The upcoming J.P. Morgan Healthcare Conference in January 2026 is expected to attract over 8,000 global participants, featuring more than 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6]. - Key trends highlighted for the industry include the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces from China [7]. Group 4: Investment Insights - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs and technology platforms from China, with average total deals from China reaching 2.756 billion USD compared to 1.289 billion USD from overseas [8]. - The pressure from patent expirations, estimated at around 300 billion USD in sales, is driving MNCs to seek high-potential assets in China, particularly in advanced fields like ADCs and cell therapies [9]. - MNCs are shifting their focus from merely acquiring products to obtaining platforms and technologies that can yield new molecules, indicating a strategic evolution in their investment approach [10]. Group 5: Key Investment Areas - Key investment areas include ADCs, GLP-1 for metabolic diseases, bispecific antibodies, and neuroscience, with a focus on companies that can deliver competitive clinical data and innovative platforms [12][13].

Core Viewpoint - The Chinese concept stock market is undergoing significant changes in 2025, characterized by a wave of privatizations and delistings from U.S. exchanges, while a number of small and medium-sized enterprises continue to seek global financing opportunities, particularly through listings in the U.S. and Hong Kong [3][4]. Group 1: Privatization and Delisting - Geely Automobile completed the privatization of Zeekr, which became a wholly-owned subsidiary and delisted from the NYSE. The privatization was marked by a rapid process, with 70.8% of Zeekr shareholders opting for shares and 29.2% for cash, totaling $701 million [6]. - Dada Group, part of the JD ecosystem, was privatized by JD Group at a valuation of $520 million, allowing for more strategic flexibility and deeper collaboration with JD in the instant retail market [7]. - Financial One Account pioneered dual delisting by completing its exit from both the NYSE and Hong Kong Stock Exchange, with a privatization deal valued at approximately HKD 1.69 billion, driven by long-term low stock prices and liquidity issues [7]. Group 2: Trends in U.S. Listings - In 2025, 63 Chinese companies went public in the U.S., raising approximately $1.12 billion, indicating a trend of increasing numbers but decreasing fundraising amounts, with an average fundraising of less than $20 million [9]. - The largest IPOs included Bawang Tea and Ascentage Pharma, raising $411 million and $126 million respectively, highlighting a shift towards smaller enterprises in the U.S. market [9][10]. - The outlook for 2026 is cautious, as new listing requirements from Nasdaq may lead to a decline in the number of Chinese companies able to meet these standards [10]. Group 3: Return to Hong Kong - The trend of Chinese companies returning to Hong Kong is gaining momentum, with companies like Pony.ai and Hesai achieving dual primary listings, which is becoming the mainstream return model [12]. - Hesai's IPO in Hong Kong was the largest in the global lidar industry to date, raising over HKD 4.16 billion (approximately $533 million) [12]. - Other companies, such as Tianjing Biopharma, are also planning to pursue dual listings in Hong Kong, indicating a broader trend of returning to Asian markets [12]. Group 4: Strategic Implications - Some analysts suggest that privatization followed by IPOs in Hong Kong or A-shares may allow companies to escape U.S. regulatory pressures and achieve better valuations in local markets [13].

Core Viewpoint - The Chinese concept stock market is undergoing significant changes in 2025, characterized by a wave of privatizations and delistings from U.S. exchanges, while a number of small and medium enterprises continue to seek global financing opportunities, reflecting a complex interplay of withdrawal and entry in the global capital market landscape [1]. Group 1: Privatization and Delisting - Geely Automobile has completed the privatization of Zeekr, which is now a wholly-owned subsidiary, and has delisted from the NYSE, with 70.8% of Zeekr shareholders opting for shares and 29.2% for cash, totaling $701 million [2]. - Dada Group, part of the JD ecosystem, was privatized at a valuation of $520 million, with the acquisition price set at $2.0 per ADS, allowing for strategic adjustments and deeper collaboration with JD in the instant retail market [3]. - Fintech company OneConnect has pioneered dual delisting, having been listed on both the NYSE and HKEX, and has now completed its delisting from both exchanges, privatized for approximately HKD 1.69 billion due to long-term low stock prices and liquidity issues [3]. Group 2: Trends in U.S. Listings - In 2025, 63 Chinese companies went public in the U.S., raising approximately $1.12 billion, marking a 41% decrease in total financing compared to 2024, despite a 7% increase in the number of new listings [4]. - The largest IPOs this year were from consumer company Bawang Chaji, raising $411 million, and pharmaceutical company Ascentage Pharma, raising $126 million, indicating a shift towards smaller enterprises in the U.S. market [4][5]. - Ascentage Pharma, which focuses on developing new small molecule drugs, became the first Chinese biotech company to list in 2025, with its stock price rising by 61.62% post-IPO [5]. Group 3: Return to Hong Kong - The trend of Chinese companies returning to Hong Kong is evident, with companies like Pony.ai and Hesai achieving dual primary listings, reflecting a shift towards this model as a means to better integrate into the Hong Kong market [6]. - Hesai's IPO in September 2025 was the largest in the global lidar industry to date, raising over HKD 4.16 billion (approximately $533 million) [6]. - Other companies, such as Tianjing Biopharma, are also planning to pursue dual listings in Hong Kong, indicating a broader trend of returning to Asian markets [6]. Group 4: Future Outlook - Some analysts suggest that certain Chinese companies may pursue privatization and then re-list in Hong Kong or A-shares to escape U.S. regulatory pressures, potentially leading to better valuations and diversified financing channels [7].

Core Insights - The Chinese concept stock market is undergoing significant changes in 2025, with notable events such as the privatization of Zeekr and Dada, as well as the dual delisting of Financial One Account, indicating a rapid withdrawal of Chinese companies from the US market while over 60 small enterprises seek global financing opportunities [1][2][3]. Group 1: Privatization and Delisting - Geely Automobile has completed the privatization of Zeekr, which is now a wholly-owned subsidiary, and has delisted from the NYSE, with 70.8% of Zeekr shareholders opting for shares and 29.2% for cash, totaling $701 million [2]. - Dada Group's privatization by JD Group at a valuation of $520 million allows for strategic adjustments and deeper collaboration with JD in the instant retail market [3]. - Financial One Account has pioneered dual delisting, completing its exit from both the NYSE and HKEX, with a privatization deal valued at approximately HK$1.69 billion, driven by long-term stock price decline and liquidity issues [3]. Group 2: Trends in US Listings - In 2025, 63 Chinese companies went public in the US, raising approximately $1.12 billion, marking a 41% decrease in fundraising compared to 2024, with an average fundraising amount of less than $20 million [4]. - The largest fundraising events were from Bawang Tea and Ascentage Pharma, raising $411 million and $126 million respectively, highlighting a shift towards smaller enterprises in the US market [4][5]. Group 3: Return to Hong Kong - The trend of Chinese companies returning to Hong Kong is evident, with companies like Pony.ai and Hesai achieving dual primary listings, indicating a preference for this model to better integrate into the Hong Kong market [6]. - Hesai's IPO raised over HK$4.16 billion (approximately $533 million), marking it as the largest IPO in the global lidar industry to date [6]. - Other companies, such as Tianjing Bio, are also planning to return to Hong Kong for dual listings, reflecting a broader trend of Chinese firms seeking to escape US regulatory pressures [6]. Group 4: Future Outlook - Analysts suggest that some Chinese concept stocks may pursue privatization and then re-list in Hong Kong or A-shares, allowing them to escape US regulatory pressures and achieve more favorable valuations in Chinese markets [7].

Group 1 - The core viewpoint of the article highlights the continuous expansion of the "Suzhou Legion" in the capital market, with Suzhou Jiangtian Packaging Technology Co., Ltd. listing on the Beijing Stock Exchange, bringing the total number of listed companies in Suzhou to 282, ranking fifth nationwide [1] - Suzhou has added 18 new domestic and foreign listed companies since 2025, with 10 of them being A-share listings, the highest among major cities in the country [1] - The strong listing momentum is attributed to Suzhou's solid industrial foundation and high-quality development ecosystem, with over 60% of companies in the A-share "Suzhou sector" focusing on emerging industries such as electronics, machinery, power, automotive, and biomedicine [1] Group 2 - In the first three quarters of 2025, Suzhou's GDP reached 19,930.21 billion yuan with a growth rate of 5.5%, leading among prefecture-level cities in the country, and the industrial added value contributed 50.9% to economic growth [2] - During the "14th Five-Year Plan" period, Suzhou is advancing new industrialization and implementing the "Suzhou Intelligent Manufacturing" project, forming a modern industrial system consisting of 10 key industrial clusters and 30 key industrial chains [2] - Suzhou has become a hub for venture capital and private equity investment, establishing a comprehensive capital support system that caters to different stages of enterprise development [2] Group 3 - Yuanhe Holdings, a well-established equity investment institution in Suzhou managing over 100 billion yuan in funds, has directly invested in 119 listed companies and has a long-term investment cycle for 205 companies [3] - The establishment of the Jiangsu Social Security Science and Technology Innovation Fund, with an initial scale of 50 billion yuan, aims to inject patient capital into Suzhou's technological innovation and economic transformation [3]

Group 1 - U.S. stocks experienced a decline, with the Dow Jones index falling approximately 0.1% on Tuesday [1] - Novo Nordisk A/S shares surged 8.6% to $52.26 following FDA approval of its Wegovy pill, marking the first approval of its kind globally [1] Group 2 - WW International Inc shares increased by 14.4% to $30.42 after launching an integrated GLP-1 program [2] - Lifezone Metals Ltd saw an 11.1% gain, reaching $4.43 [2] - Hycroft Mining Holding Corporation shares rose 9.1% to $26.75 [2] - Sable Offshore Corp gained 8.8% to $8.27 after receiving approval for the restart plans of the Las Flores Pipeline system [2] - Ascentage Pharma Group International shares increased by 8.4% to $28.17 [2] - Lionsgate Studios Corp shares surged 8.3% to $9.06 after expanding access to its ad-supported streaming inventory [2] - Critical Metals Corp gained 7.6% to $8.65 [2] - ZIM Integrated Shipping Services Ltd shares rose 7.4% to $21.35 after receiving acquisition proposals and evaluating offers [2] - mF International Limited shares increased by 7.1% to $21.38 [2] - Intrepid Potash Inc shares rose 7.1% to $29.06 [2] - Sellas Life Sciences Group Inc gained 6.8% to $2.82 [2] - StoneCo Ltd shares increased by 5.8% to $14.96 after the board authorized a new share repurchase program of up to R$2 billion [2] - Century Aluminum Co shares rose 5% to $39.02, with Wells Fargo analyst maintaining an Overweight rating and raising the price target from $37 to $46 [2]

Core Viewpoint - The "Annual Outstanding Biopharmaceutical Company" award was presented to Ascentage Pharma (06855.HK/AAPG.US) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by Gelonghui on December 22 [1] Group 1 - The award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications in the biopharmaceutical field [1] - The evaluation criteria for the award include technological innovation, research and development strength, and the ability to translate results into practical applications [1]